This article was originally published on PharmaTimes http://www.pharmatimes.com/news/another_mid-late_stage_alzheimers_flop,_this_time_for_lilly_1325629

Earlier this month, Roche also announced a gantenerumab Alzheimer’s failure, and last year, Biogen and Eisai stopped two global Phase III trials of aducanumab.

Related Posts